Heron Therapeutics Announces Third Quarter 2024 Financial Results Plans
Heron Therapeutics, Inc. (NASDAQ: HRTX), a company positioned at the forefront of biotechnology, is gearing up to release its financial results for the third quarter of 2024. This exciting announcement will take place during a dedicated conference call set for a Tuesday morning in November, where the leadership team will share key insights and updates.
Conference Call Details
This important call is scheduled to commence at 8:00 a.m. ET and will serve as a platform not only to present the financial numbers but also to discuss recent business achievements. Participants interested in joining the conference call will be able to easily access it through a registration link. To ensure smooth participation, they are encouraged to join at least fifteen minutes before the event begins.
Webcast Availability
For those who prefer digital access, the webcast will be available via Heron Therapeutics' Investor Relations section on their website. This provides an alternative to the phone line, offering flexibility to the attendees. Additionally, a recorded archive of the teleconference and webcast will be accessible online for 60 days after the event, allowing stakeholders to stay informed at their convenience.
Understanding Heron Therapeutics
Heron Therapeutics, Inc. stands out as a commercial-stage biotechnology firm dedicated to enhancing patient care. With its sights set on optimizing therapeutic innovations, the company is committed to not just treating conditions but improving overall medical outcomes for patients. This inspiration drives the company to develop and market cutting-edge therapies aimed at elevating standards of care in oncology and acute medical situations.
Innovative Product Portfolio
The company boasts a diverse range of products that signify a leap forward in medication standards. By leveraging advanced scientific principles and proprietary technologies, Heron Therapeutics has carved out a significant presence in the biotechnology landscape. This firm commitment reflects their pursuit of excellence in drug development and a steadfast focus on addressing unmet medical needs.
Commitment to Transparency
As an integral part of public communications, Heron values transparency and accountability. While the company has made significant strides in its research and product development efforts, it is also aware of the inherent risks and uncertainties that can influence market outcomes. Heron Therapeutics emphasizes that its statements regarding future performance stem from current expectations, which are subject to change based on ongoing challenges.
Investor Relations Team
For inquiries, the Investor Relations and Media Contact for Heron is Ira Duarte, who serves as the Executive Vice President and Chief Financial Officer. The company maintains open lines of communication to ensure that stakeholders have timely access to necessary information regarding their operations and market initiatives.
Frequently Asked Questions
What is the purpose of Heron's upcoming conference call?
The upcoming conference call aims to report Heron Therapeutics' financial results for the third quarter of 2024 and discuss recent business developments.
How can I access the conference call?
Participants can access the call via a registration link which provides dial-in details and webcast options on Heron's website.
Why is Heron Therapeutics focused on biotechnology?
Heron Therapeutics focuses on biotechnology to develop innovative therapies that significantly enhance patient care and medical outcomes, especially in oncology and acute care.
How does Heron communicate with its stakeholders?
Heron Therapeutics maintains transparent communication through conference calls, webcasts, and its Investor Relations section on the company website.
Who can I contact for more information?
For more information, Ira Duarte can be reached as the Investor Relations contact for Heron Therapeutics.
